Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 131

1.

Circulating Tumor Cells as a Prognostic Factor in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: the CIRCUTEC Prospective Study.

Garrel R, Mazel M, Perriard F, Vinches M, Cayrefourcq L, Guigay J, Digue L, Aubry K, Alfonsi M, Delord JP, Lallemant B, Even C, Daurès JP, Landais P, Cupissol D, Alix-Panabières C.

Clin Chem. 2019 Aug 6. pii: clinchem.2019.305904. doi: 10.1373/clinchem.2019.305904. [Epub ahead of print]

PMID:
31387885
2.

Corrigendum to 'A phase 1b study of afatinib in combination with standard-dose cetuximab in patients with advanced solid tumours' [Eur J Cancer 104 (November 2018) 1-8].

Gazzah A, Boni V, Soria JC, Calles A, Even C, Doger B, Mahjoubi L, Bahleda R, Ould-Kaci M, Esler A, Nazabadioko S, Calvo E.

Eur J Cancer. 2019 Jul 30. pii: S0959-8049(18)31564-8. doi: 10.1016/j.ejca.2018.12.018. [Epub ahead of print] No abstract available.

PMID:
31375258
3.

Nivolumab in Patients with Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck: Efficacy and Safety in CheckMate 141 by Prior Cetuximab Use.

Ferris RL, Licitra L, Fayette J, Even C, Blumenschein G Jr, Harrington KJ, Guigay J, Vokes EE, Saba NF, Haddad R, Ramkumar S, Russell J, Brossart P, Tahara M, Colevas AD, Concha-Benavente F, Lynch M, Li L, Gillison ML.

Clin Cancer Res. 2019 Sep 1;25(17):5221-5230. doi: 10.1158/1078-0432.CCR-18-3944. Epub 2019 Jun 25.

PMID:
31239321
4.

Afatinib vs Placebo as Adjuvant Therapy After Chemoradiotherapy in Squamous Cell Carcinoma of the Head and Neck: A Randomized Clinical Trial.

Burtness B, Haddad R, Dinis J, Trigo J, Yokota T, de Souza Viana L, Romanov I, Vermorken J, Bourhis J, Tahara M, Martins Segalla JG, Psyrri A, Vasilevskaya I, Nangia CS, Chaves-Conde M, Kiyota N, Homma A, Holeckova P, Del Campo JM, Asarawala N, Nicolau UR, Rauch D, Even C, Wang B, Gibson N, Ehrnrooth E, Harrington K, Cohen EEW; LUX-Head & Neck 2 investigators.

JAMA Oncol. 2019 Jun 13. doi: 10.1001/jamaoncol.2019.1146. [Epub ahead of print]

PMID:
31194247
5.

Anemia and neutrophil-to-lymphocyte ratio in laryngeal cancer treated with induction chemotherapy.

Gorphe P, Bouhir S, Garcia GCTE, Alali A, Even C, Breuskin I, Tao Y, Janot F, Bidault F, Temam S.

Laryngoscope. 2019 Apr 22. doi: 10.1002/lary.28021. [Epub ahead of print]

PMID:
31006874
6.

Safety and clinical activity of the Notch inhibitor, crenigacestat (LY3039478), in an open-label phase I trial expansion cohort of advanced or metastatic adenoid cystic carcinoma.

Even C, Lassen U, Merchan J, Le Tourneau C, Soria JC, Ferte C, Ricci F, Diener JT, Yuen E, Smith C, Oakley GJ 3rd, Benhadji KA, Massard C.

Invest New Drugs. 2019 Apr 6. doi: 10.1007/s10637-019-00739-x. [Epub ahead of print]

PMID:
30953269
7.

Computed tomography evaluation after induction chemotherapy for T3 laryngeal cancer: Does response correlate with vocal cord mobility?

Garcia GCTE, Gorphe P, Hartl D, Ammari S, Even C, Tao Y, Balleyguier C, Varoquaux A, Bidault F.

Oral Oncol. 2019 Mar;90:13-16. doi: 10.1016/j.oraloncology.2019.01.009. Epub 2019 Jan 28.

PMID:
30846170
8.

New approaches in salivary gland carcinoma.

Even C, Baste N, Classe M.

Curr Opin Oncol. 2019 May;31(3):169-174. doi: 10.1097/CCO.0000000000000527.

PMID:
30844885
9.

Successful treatment with trastuzumab in HER2-positive squamous cell carcinoma of the head and neck.

Saleh K, Saada E, Auger N, Mayache-Badis L, Casiraghi O, Bidault F, Bahleda R, Even C.

Oral Oncol. 2019 Apr;91:129-131. doi: 10.1016/j.oraloncology.2019.02.008. Epub 2019 Feb 14. No abstract available.

PMID:
30773349
10.

Prognostic factors in patients with soft palate squamous cell carcinoma.

Schernberg A, Canova C, Blanchard P, Gorphe P, Breuskin I, Mirghani H, Moya-Plana A, Janot F, Bidault F, Chargari C, Bellefqih S, Ruffier A, Even C, Nguyen F, Temam S, Tao Y.

Head Neck. 2019 May;41(5):1441-1449. doi: 10.1002/hed.25598. Epub 2019 Jan 12.

PMID:
30636178
11.

Durvalumab for recurrent or metastatic head and neck squamous cell carcinoma: Results from a single-arm, phase II study in patients with ≥25% tumour cell PD-L1 expression who have progressed on platinum-based chemotherapy.

Zandberg DP, Algazi AP, Jimeno A, Good JS, Fayette J, Bouganim N, Ready NE, Clement PM, Even C, Jang RW, Wong S, Keilholz U, Gilbert J, Fenton M, Braña I, Henry S, Remenar E, Papai Z, Siu LL, Jarkowski A, Armstrong JM, Asubonteng K, Fan J, Melillo G, Mesía R.

Eur J Cancer. 2019 Jan;107:142-152. doi: 10.1016/j.ejca.2018.11.015. Epub 2018 Dec 18.

12.

Safety and Efficacy of Durvalumab With or Without Tremelimumab in Patients With PD-L1-Low/Negative Recurrent or Metastatic HNSCC: The Phase 2 CONDOR Randomized Clinical Trial.

Siu LL, Even C, Mesía R, Remenar E, Daste A, Delord JP, Krauss J, Saba NF, Nabell L, Ready NE, Braña I, Kotecki N, Zandberg DP, Gilbert J, Mehanna H, Bonomi M, Jarkowski A, Melillo G, Armstrong JM, Wildsmith S, Fayette J.

JAMA Oncol. 2019 Feb 1;5(2):195-203. doi: 10.1001/jamaoncol.2018.4628.

PMID:
30383184
13.

A phase 1b study of afatinib in combination with standard-dose cetuximab in patients with advanced solid tumours.

Gazzah A, Boni V, Soria JC, Calles A, Even C, Doger B, Mahjoubi L, Bahleda R, Ould-Kaci M, Esler A, Nazabadioko S, Calvo E.

Eur J Cancer. 2018 Nov;104:1-8. doi: 10.1016/j.ejca.2018.07.011. Epub 2018 Oct 1. Erratum in: Eur J Cancer. 2019 Jul 30;:.

PMID:
30278378
14.

High incidence of cetuximab-related infusion reactions in head and neck patients.

Palomar Coloma V, Bravo P, Lezghed N, Mayache-Badis L, Herrera Gómez RG, Iacob M, Nicouleau L, Desmaris R, Tao Y, Leibu C, Matias M, Lemare F, Even C, Annereau M, Ferté C.

ESMO Open. 2018 Jul 23;3(5):e000346. doi: 10.1136/esmoopen-2018-000346. eCollection 2018.

15.

[New developments in the management of nasopharyngeal carcinoma].

Blanchard P, Nguyen F, Moya-Plana A, Pignon JP, Even C, Bidault F, Temam S, Ruffier A, Tao Y.

Cancer Radiother. 2018 Oct;22(6-7):492-495. doi: 10.1016/j.canrad.2018.06.003. Epub 2018 Aug 4. Review. French.

PMID:
30087054
16.

Nivolumab vs investigator's choice in recurrent or metastatic squamous cell carcinoma of the head and neck: 2-year long-term survival update of CheckMate 141 with analyses by tumor PD-L1 expression.

Ferris RL, Blumenschein G Jr, Fayette J, Guigay J, Colevas AD, Licitra L, Harrington KJ, Kasper S, Vokes EE, Even C, Worden F, Saba NF, Docampo LCI, Haddad R, Rordorf T, Kiyota N, Tahara M, Lynch M, Jayaprakash V, Li L, Gillison ML.

Oral Oncol. 2018 Jun;81:45-51. doi: 10.1016/j.oraloncology.2018.04.008. Epub 2018 Apr 17.

17.

CheckMate 141: 1-Year Update and Subgroup Analysis of Nivolumab as First-Line Therapy in Patients with Recurrent/Metastatic Head and Neck Cancer.

Gillison ML, Blumenschein G Jr, Fayette J, Guigay J, Colevas AD, Licitra L, Harrington KJ, Kasper S, Vokes EE, Even C, Worden F, Saba NF, Iglesias Docampo LC, Haddad R, Rordorf T, Kiyota N, Tahara M, Monga M, Lynch M, Li L, Ferris RL.

Oncologist. 2018 Sep;23(9):1079-1082. doi: 10.1634/theoncologist.2017-0674. Epub 2018 Jun 4.

18.

Randomized trial comparing two methods of re-irradiation after salvage surgery in head and neck squamous cell carcinoma: Once daily split-course radiotherapy with concomitant chemotherapy or twice daily radiotherapy with cetuximab.

Tao Y, Faivre L, Laprie A, Boisselier P, Ferron C, Jung GM, Racadot S, Gery B, Even C, Breuskin I, Bourhis J, Janot F.

Radiother Oncol. 2018 Sep;128(3):467-471. doi: 10.1016/j.radonc.2018.05.005. Epub 2018 May 18.

PMID:
29784451
19.

Does smoking alter the mutation profile of human papillomavirus-driven head and neck cancers?

Mirghani H, Lacroix L, Rossoni C, Sun R, Aupérin A, Casiraghi O, Villepelet A, Lacave R, Faucher G, Marty V, Ferté C, Soria JC, Even C.

Eur J Cancer. 2018 May;94:61-69. doi: 10.1016/j.ejca.2018.02.013. Epub 2018 Mar 20.

PMID:
29533868
20.

TPF induction chemotherapy increases PD-L1 expression in tumour cells and immune cells in head and neck squamous cell carcinoma.

Leduc C, Adam J, Louvet E, Sourisseau T, Dorvault N, Bernard M, Maingot E, Faivre L, Cassin-Kuo MS, Boissier E, Dessoliers MC, Robin A, Casiraghi O, Even C, Temam S, Olaussen KA, Soria JC, Postel-Vinay S.

ESMO Open. 2018 Jan 9;3(1):e000257. doi: 10.1136/esmoopen-2017-000257. eCollection 2018.

21.

Stability of the diagnosis of seasonal affective disorder in a long-term prospective study.

Cléry-Melin ML, Gorwood P, Friedman S, Even C.

J Affect Disord. 2018 Feb;227:353-357. doi: 10.1016/j.jad.2017.11.014. Epub 2017 Nov 7.

PMID:
29145077
22.

Cabazitaxel in recurrent/metastatic squamous cell carcinoma of the head and neck: phase II UNICANCER trial ORL03.

Fayette J, Guigay J, Le Tourneau C, Degardin M, Peyrade F, Neidhardt EM, Sablin MP, Even C, Orlandini F, Juzyna B, Bellera C.

Oncotarget. 2017 Mar 4;8(31):51830-51839. doi: 10.18632/oncotarget.15901. eCollection 2017 Aug 1.

23.

Safety and Antitumor Activity of Pembrolizumab in Patients With Programmed Death-Ligand 1-Positive Nasopharyngeal Carcinoma: Results of the KEYNOTE-028 Study.

Hsu C, Lee SH, Ejadi S, Even C, Cohen RB, Le Tourneau C, Mehnert JM, Algazi A, van Brummelen EMJ, Saraf S, Thanigaimani P, Cheng JD, Hansen AR.

J Clin Oncol. 2017 Dec 20;35(36):4050-4056. doi: 10.1200/JCO.2017.73.3675. Epub 2017 Aug 24.

PMID:
28837405
24.

Mutation in the Core Structure of Desmin Intermediate Filaments Affects Myoblast Elasticity.

Even C, Abramovici G, Delort F, Rigato AF, Bailleux V, de Sousa Moreira A, Vicart P, Rico F, Batonnet-Pichon S, Briki F.

Biophys J. 2017 Aug 8;113(3):627-636. doi: 10.1016/j.bpj.2017.06.020.

25.

Recent advances in studying single bacteria and biofilm mechanics.

Even C, Marlière C, Ghigo JM, Allain JM, Marcellan A, Raspaud E.

Adv Colloid Interface Sci. 2017 Sep;247:573-588. doi: 10.1016/j.cis.2017.07.026. Epub 2017 Jul 21. Review.

PMID:
28754382
26.

Nivolumab versus standard, single-agent therapy of investigator's choice in recurrent or metastatic squamous cell carcinoma of the head and neck (CheckMate 141): health-related quality-of-life results from a randomised, phase 3 trial.

Harrington KJ, Ferris RL, Blumenschein G Jr, Colevas AD, Fayette J, Licitra L, Kasper S, Even C, Vokes EE, Worden F, Saba NF, Kiyota N, Haddad R, Tahara M, Grünwald V, Shaw JW, Monga M, Lynch M, Taylor F, DeRosa M, Morrissey L, Cocks K, Gillison ML, Guigay J.

Lancet Oncol. 2017 Aug;18(8):1104-1115. doi: 10.1016/S1470-2045(17)30421-7. Epub 2017 Jun 23.

27.

Hyperprogression during anti-PD-1/PD-L1 therapy in patients with recurrent and/or metastatic head and neck squamous cell carcinoma.

Saâda-Bouzid E, Defaucheux C, Karabajakian A, Coloma VP, Servois V, Paoletti X, Even C, Fayette J, Guigay J, Loirat D, Peyrade F, Alt M, Gal J, Le Tourneau C.

Ann Oncol. 2017 Jul 1;28(7):1605-1611. doi: 10.1093/annonc/mdx178.

PMID:
28419181
28.

High-Throughput Genomics and Clinical Outcome in Hard-to-Treat Advanced Cancers: Results of the MOSCATO 01 Trial.

Massard C, Michiels S, Ferté C, Le Deley MC, Lacroix L, Hollebecque A, Verlingue L, Ileana E, Rosellini S, Ammari S, Ngo-Camus M, Bahleda R, Gazzah A, Varga A, Postel-Vinay S, Loriot Y, Even C, Breuskin I, Auger N, Job B, De Baere T, Deschamps F, Vielh P, Scoazec JY, Lazar V, Richon C, Ribrag V, Deutsch E, Angevin E, Vassal G, Eggermont A, André F, Soria JC.

Cancer Discov. 2017 Jun;7(6):586-595. doi: 10.1158/2159-8290.CD-16-1396. Epub 2017 Apr 1.

29.

Long-term response in patient with recurrent oropharyngeal carcinoma treated with cetuximab, docetaxel and cisplatin (TPEx) as first-line treatment followed by cetuximab maintenance.

Guigay J, Even C, Mayache-Badis L, Debbah M, Saada-Bouzid E, Tao Y, Deschamps F, Janot F, Lezghed N, Michel C.

Oral Oncol. 2017 May;68:114-118. doi: 10.1016/j.oraloncology.2017.03.009. Epub 2017 Mar 24.

PMID:
28347701
30.

Relationship between the time to locoregional recurrence and survival in laryngeal squamous-cell carcinoma.

Gorphe P, Tao Y, Blanchard P, Even C, Moya-Plana A, Mirghani H, Nguyen F, Temam S, Janot F.

Eur Arch Otorhinolaryngol. 2017 May;274(5):2267-2271. doi: 10.1007/s00405-017-4473-3. Epub 2017 Feb 9.

PMID:
28185009
31.

Outcomes and prognostic factors for squamous cell carcinoma of the oral tongue in young adults: a single-institution case-matched analysis.

Blanchard P, Belkhir F, Temam S, El Khoury C, De Felice F, Casiraghi O, Patrikidou A, Mirghani H, Levy A, Even C, Gorphe P, Nguyen F, Janot F, Tao Y.

Eur Arch Otorhinolaryngol. 2017 Mar;274(3):1683-1690. doi: 10.1007/s00405-016-4419-1. Epub 2016 Dec 8.

PMID:
27933385
32.

Laryngo-esophageal Dysfunction-free Survival in a Preservation Protocol for T3 Laryngeal Squamous-cell Carcinoma.

Gorphe P, Matias M, Even C, Ferte C, Bidault F, Garcia G, Temam S, Nguyen F, Blanchard P, Tao Y, Janot F.

Anticancer Res. 2016 Dec;36(12):6625-6630.

PMID:
27919993
33.

Outcomes following laryngectomy refusal after insufficient response to induction chemotherapy.

Gorphe P, Matias M, Blanchard P, Even C, Ferte C, Tao Y, Temam S, Bidault F, Janot F.

Laryngoscope. 2017 Aug;127(8):1791-1796. doi: 10.1002/lary.26425. Epub 2016 Nov 26.

PMID:
27888508
34.

Induction chemotherapy with docetaxel, cisplatin and fluorouracil followed by concurrent chemoradiotherapy or chemoradiotherapy alone in locally advanced non-endemic nasopharyngeal carcinoma.

Ou D, Blanchard P, El Khoury C, De Felice F, Even C, Levy A, Nguyen F, Janot F, Gorphe P, Deutsch E, Temam S, Tao Y.

Oral Oncol. 2016 Nov;62:114-121. doi: 10.1016/j.oraloncology.2016.10.011. Epub 2016 Oct 22.

PMID:
27865364
35.

Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck.

Ferris RL, Blumenschein G Jr, Fayette J, Guigay J, Colevas AD, Licitra L, Harrington K, Kasper S, Vokes EE, Even C, Worden F, Saba NF, Iglesias Docampo LC, Haddad R, Rordorf T, Kiyota N, Tahara M, Monga M, Lynch M, Geese WJ, Kopit J, Shaw JW, Gillison ML.

N Engl J Med. 2016 Nov 10;375(19):1856-1867. Epub 2016 Oct 8.

36.

[Oral cavity cancers among young people: Clinical results and prognostic analysis].

Blanchard P, El Khoury C, Temam S, Casiraghi O, Mirghani H, Lévy A, Gorphe P, Éven C, De Felice F, Nguyen F, Janot F, Tao Y.

Cancer Radiother. 2016 Apr;20(2):91-7. doi: 10.1016/j.canrad.2015.09.013. Epub 2016 Mar 8. French.

PMID:
26969246
37.

[Mucosal melanomas of the head and neck: State of the art and current controversies].

Troussier I, Baglin AC, Marcy PY, Even C, Moya-Plana A, Krengli M, Thariat J.

Bull Cancer. 2015 Jun;102(6):559-67. doi: 10.1016/j.bulcan.2015.04.013. Epub 2015 May 26. French.

PMID:
26022288
38.

Trabectedin in patients with advanced soft tissue sarcoma: a retrospective national analysis of the French Sarcoma Group.

Le Cesne A, Ray-Coquard I, Duffaud F, Chevreau C, Penel N, Bui Nguyen B, Piperno-Neumann S, Delcambre C, Rios M, Chaigneau L, Le Maignan C, Guillemet C, Bertucci F, Bompas E, Linassier C, Olivier T, Kurtz JE, Even C, Cousin P, Yves Blay J; French Sarcoma Group.

Eur J Cancer. 2015 Apr;51(6):742-50. doi: 10.1016/j.ejca.2015.01.006. Epub 2015 Feb 23.

PMID:
25727882
39.

Actinomycin D, cisplatin, and etoposide regimen is associated with almost universal cure in patients with high-risk gestational trophoblastic neoplasia.

Even C, Pautier P, Duvillard P, Floquet A, Kerbrat P, Troalen F, Rey A, Balleyguier C, Tazi Y, Leary A, Augereau P, Morice P, Droz JP, Fizazi K, Lhommé C.

Eur J Cancer. 2014 Aug;50(12):2082-9. doi: 10.1016/j.ejca.2014.05.002. Epub 2014 Jun 5.

PMID:
24910417
40.

Adult attention-deficit/hyperactivity disorder in major depressed and bipolar subjects: role of personality traits and clinical implications.

Di Nicola M, Sala L, Romo L, Catalano V, Even C, Dubertret C, Martinotti G, Camardese G, Mazza M, Tedeschi D, Callea A, De Risio L, Guelfi JD, Rouillon F, Janiri L, Gorwood P.

Eur Arch Psychiatry Clin Neurosci. 2014 Aug;264(5):391-400. doi: 10.1007/s00406-013-0456-6.

PMID:
24077910
41.

Retinoic acid receptor alpha amplifications and retinoic acid sensitivity in breast cancers.

Alsafadi S, Even C, Falet C, Goubar A, Commo F, Scott V, Quidville V, Albiges L, Dieci MV, Guegan J, Lazar V, Ahomadegbe JC, Delaloge S, André F.

Clin Breast Cancer. 2013 Oct;13(5):401-8. doi: 10.1016/j.clbc.2013.02.001. Epub 2013 Jul 3.

PMID:
23830798
42.

Recombinant erythropoietin for the anaemia of patients with advanced Gastrointestinal Stromal Tumours (GIST) receiving imatinib: an active agent only in non progressive patients.

Duffaud F, Even C, Ray-Coquard I, Bompas E, Khoa-Huynh T, Salas S, Cassier P, Dufresne A, Bonvalot S, Ducimetiere F, Le Cesne A, Blay JY.

Clin Sarcoma Res. 2012 Sep 5;2(1):11. doi: 10.1186/2045-3329-2-11.

43.

Is depression in Parkinson's disease (PD) a specific entity?

Even C, Weintraub D.

J Affect Disord. 2012 Jul;139(2):103-12. doi: 10.1016/j.jad.2011.07.002. Epub 2011 Jul 26. Review.

PMID:
21794923
44.

[Ovarian yolk sac tumour: general review].

Even C, Lhommé C, Duvillard P, Morice P, Balleyguier C, Pautier P, Troalen F, de La Motte Rouge T.

Bull Cancer. 2011 Aug;98(8):963-75. doi: 10.1684/bdc.2011.1387. Review. French.

45.

[Information, education, psycho-education for bipolar disorders. Yes, we should].

Even C.

Encephale. 2011 May;37 Suppl 1:S1-3. doi: 10.1016/j.encep.2009.11.001. Epub 2010 Jan 6. French. No abstract available.

PMID:
21600327
46.

Association of the intronic rs2072621 polymorphism of the X-linked GPR50 gene with affective disorder with seasonal pattern.

Delavest M, Even C, Benjemaa N, Poirier MF, Jockers R, Krebs MO.

Eur Psychiatry. 2012 Jul;27(5):369-71. doi: 10.1016/j.eurpsy.2011.02.011. Epub 2011 May 11.

PMID:
21565467
47.

[DSM-5: new classification, new… and old problems].

Even C.

Encephale. 2011 Apr;37(2):83-5. doi: 10.1016/j.encep.2010.08.002. French. No abstract available.

PMID:
21482224
48.

Single-file diffusion of interacting particles in a finite-sized channel.

Delfau JB, Coste C, Even C, Saint Jean M.

Phys Rev E Stat Nonlin Soft Matter Phys. 2010 Sep;82(3 Pt 1):031201. Epub 2010 Sep 20.

PMID:
21230062
49.

[Antepartum depression: prevalence, diagnosis and treatment].

Chatillon O, Even C.

Encephale. 2010 Dec;36(6):443-51. doi: 10.1016/j.encep.2010.02.004. Epub 2010 Apr 7. Review. French.

PMID:
21130227
50.

Impact of invasive fungal disease on the chemotherapy schedule and event-free survival in acute leukemia patients who survived fungal disease: a case-control study.

Even C, Bastuji-Garin S, Hicheri Y, Pautas C, Botterel F, Maury S, Cabanne L, Bretagne S, Cordonnier C.

Haematologica. 2011 Feb;96(2):337-41. doi: 10.3324/haematol.2010.030825. Epub 2010 Nov 11.

Supplemental Content

Support Center